PARADIGM study meets primary endpoint.
US non-profit organisation to begin late-stage trials this year
But Zynerba’s cannabis epilepsy drug fails in phase 2.
App improves episodic memory by 40%.
Investors concerned over strong placebo effect
Patients to get Santhera’s Raxone under EAMS scheme.
Mydadis approval ends decade-long saga with FDA.